A detailed history of Oak Associates LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Oak Associates LTD holds 4,759 shares of VRTX stock, worth $2.24 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
4,759
Previous 4,859 2.06%
Holding current value
$2.24 Million
Previous $2.03 Million 9.8%
% of portfolio
0.15%
Previous 0.14%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$392.81 - $485.53 $39,281 - $48,553
-100 Reduced 2.06%
4,759 $2.23 Million
Q1 2024

May 10, 2024

SELL
$407.69 - $446.08 $814,564 - $891,267
-1,998 Reduced 29.14%
4,859 $2.03 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $122,451 - $146,612
-357 Reduced 4.95%
6,857 $2.79 Million
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $74,399 - $79,741
-220 Reduced 2.96%
7,214 $2.51 Million
Q2 2023

Aug 11, 2023

SELL
$314.42 - $351.91 $182,992 - $204,811
-582 Reduced 7.26%
7,434 $2.62 Million
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $308,154 - $351,532
1,088 Added 15.7%
8,016 $2.53 Million
Q4 2022

Feb 09, 2023

BUY
$285.76 - $321.48 $200,032 - $225,036
700 Added 11.24%
6,928 $2 Million
Q1 2022

May 12, 2022

SELL
$221.42 - $260.97 $39,412 - $46,452
-178 Reduced 2.78%
6,228 $1.63 Million
Q4 2021

Feb 10, 2022

SELL
$177.01 - $223.45 $88,505 - $111,725
-500 Reduced 7.24%
6,406 $1.41 Million
Q2 2021

Aug 09, 2021

SELL
$187.49 - $221.1 $54,559 - $64,340
-291 Reduced 4.04%
6,906 $1.39 Million
Q1 2021

May 13, 2021

BUY
$207.02 - $241.31 $30,431 - $35,472
147 Added 2.09%
7,197 $1.55 Million
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $2.5 Million - $3.34 Million
-12,090 Reduced 63.17%
7,050 $1.67 Million
Q3 2020

Nov 13, 2020

BUY
$255.65 - $303.1 $15,339 - $18,186
60 Added 0.31%
19,140 $5.21 Million
Q2 2020

Aug 11, 2020

BUY
$225.48 - $295.8 $4.3 Million - $5.64 Million
19,080 New
19,080 $5.54 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Oak Associates LTD Portfolio

Follow Oak Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oak Associates LTD , based on Form 13F filings with the SEC.

News

Stay updated on Oak Associates LTD with notifications on news.